ViiV’s Fostemsavir Loses EU Fast-Track Status
Potential New HIV Treatment Reverts To Standard Review
Viiv Healthcare's marketing application for fostemsavir started off being fast-tracked through the review process at the European Medicines Agency in January but is now being reviewed under standard timelines. The product is being developed for the treatment of adults with multidrug resistant HIV-1 infection.
